Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Combined hepatoprotective therapy of liver diseases

View through CrossRef
The combined use of hepatoprotectors may aim to expand the spectrum of hepatotropic action or unidirectionally increase a particular pharmacological effect due to summation or potentiation (synergism). An example of the combined effects of ademetionine and silymarin is a study that showed for the first time that the combination of ademetionine and silybinin inhibits inflammation and oxidative stress through two separate signaling pathways. Both ademetionine and silymarin inhibit the accumulation of fat in the liver, which was confirmed in a pilot clinical study. In patients with metabolic‑associated steatotic liver disease, treatment with a combination of hepatoprotectors reduced the degree of liver steatosis according to ultrasound. The synergistic effect of the combination is reflected in the treatment of depression in steatotic liver disease and the agonistic effect on the farnesoid receptor in alcoholic liver disease. The effectiveness of the combination in alcoholic hepatopathies has been proven in a clinical trial. Expanding the spectrum of therapeutic action in the combination of ademetionine and silymarin is due to the fact that despite the effectiveness of both drugs in toxic, drug‑induced liver damage, there are situations when it is more appropriate to prescribe one or the other drug. For example, silymarin is effective in death cap poisoning, while ademetionine is not. Ademetionine is effective in intrahepatic cholestasis, while silymarin is not. Other properties of silymarin are also important, as they enable the combination to expand the range of effects: antifibrotic, antitumor, immunomodulatory, choleretic, antiviral, and participation in the regulation of apoptosis and hepatocyte regeneration. Long‑term treatment with both ademetionine and silymarin help to prolong the life of patients with liver cirrhosis. Thus, the combination of ademetionine and silymarin (Adenomak Plus) is pathogenetically sound, effective, and promising, based on evidence‑based research.  
Title: Combined hepatoprotective therapy of liver diseases
Description:
The combined use of hepatoprotectors may aim to expand the spectrum of hepatotropic action or unidirectionally increase a particular pharmacological effect due to summation or potentiation (synergism).
An example of the combined effects of ademetionine and silymarin is a study that showed for the first time that the combination of ademetionine and silybinin inhibits inflammation and oxidative stress through two separate signaling pathways.
Both ademetionine and silymarin inhibit the accumulation of fat in the liver, which was confirmed in a pilot clinical study.
In patients with metabolic‑associated steatotic liver disease, treatment with a combination of hepatoprotectors reduced the degree of liver steatosis according to ultrasound.
The synergistic effect of the combination is reflected in the treatment of depression in steatotic liver disease and the agonistic effect on the farnesoid receptor in alcoholic liver disease.
The effectiveness of the combination in alcoholic hepatopathies has been proven in a clinical trial.
Expanding the spectrum of therapeutic action in the combination of ademetionine and silymarin is due to the fact that despite the effectiveness of both drugs in toxic, drug‑induced liver damage, there are situations when it is more appropriate to prescribe one or the other drug.
For example, silymarin is effective in death cap poisoning, while ademetionine is not.
Ademetionine is effective in intrahepatic cholestasis, while silymarin is not.
Other properties of silymarin are also important, as they enable the combination to expand the range of effects: antifibrotic, antitumor, immunomodulatory, choleretic, antiviral, and participation in the regulation of apoptosis and hepatocyte regeneration.
Long‑term treatment with both ademetionine and silymarin help to prolong the life of patients with liver cirrhosis.
Thus, the combination of ademetionine and silymarin (Adenomak Plus) is pathogenetically sound, effective, and promising, based on evidence‑based research.
 .

Related Results

[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED]Product Name - Bridport Health Ingredients - Milk Thistle, Beetroot, Artichoke Extract & More. Category - Liver Support Supplement Main Benefits - Helps Protect The ...
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED]Depiction • Where to Get Bottle Online –Click Here • Item Name -Bridport Health Liver • Aftereffects - No Major Side Effects • Classification - Health • Accessibility -O...
Hepatoprotective activity of Ammi majus on CCL4 Induced Albino Mice
Hepatoprotective activity of Ammi majus on CCL4 Induced Albino Mice
This study was amid to evaluate the possible protective effects of the water and alcoholic extract of Ammi majus seeds against liver damage induced in mice by CCL4. The plant was c...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Requirement of vasculogenesis and blood circulation in late stages of liver growth in zebrafish
Requirement of vasculogenesis and blood circulation in late stages of liver growth in zebrafish
Abstract Background Early events in vertebrate liver development have been the major focus in previous studies, however, late events of liver organo...
EVALUATION AND COMPARISON OF LIVER MARKERS IN ACUTE LIVER FAILURE VS CHRONIC LIVER FAILURE IN DISTRICT FAISALABAD: A CROSS-SECTIONAL STUDY
EVALUATION AND COMPARISON OF LIVER MARKERS IN ACUTE LIVER FAILURE VS CHRONIC LIVER FAILURE IN DISTRICT FAISALABAD: A CROSS-SECTIONAL STUDY
Background: Liver failure is a life-threatening clinical condition resulting from the inability of the liver to maintain its metabolic, synthetic, and detoxification functions. Acu...
Hepatoprotective Activities of Colocasia esculenta (L.) Schottin Mice Model with Liver Injury Induced by Paracetamol
Hepatoprotective Activities of Colocasia esculenta (L.) Schottin Mice Model with Liver Injury Induced by Paracetamol
This paper uses the model of experimental mouse liver damage with paracetamol to evaluate the liver protective effects of the methanol extract (Colocasia esculenta (L.) Schott) (MC...

Back to Top